Rob Grownkowski latest NFL player to endorse CBD for athletes

Rob Gronkowski discovered CBD while recovering from various injuries as a Super Bowl-winning tight end with the New England Patriots.

Super Bowl-winning tight end Rob Gronkowski is among the latest of football players to end their careers early, then turn around and endorse cannabis-based medicine. At 30 years old, Gronkowski, more commonly known by his nickname “Gronk,” the former New England Patriot will now become an advocate for players to use CBD as a pain management tool and anti-inflammatory.

While he said “physically, I could play right now,” Gronk added that he isn’t there mentally or emotionally to suit up again. Gronk said using CBD following his retirement from professional football in March has allowed him to be pain free for the first time in years.

“I’m advocating for CBD to be acceptable for all players for recovery,” he said. “You can just call me Mr. Recovery. You know you like that name. Mr. Recovery, baby.”

Gronkowski’s comment came at a formal press conference to announce his investment and partnership with Abacus Health, which sells a line of “all-natural, fitness-oriented recovery products.” On its website, the company promotes various CBD-infused products, including a pain stick, massage oils, and ointments. CBD, and cannabis as a whole, is said to assist in football players recovery, reducing inflammation and pain. In addition, there is also growing evidence that CBD can assist the healing process of suffering traumatic brain.

However, Gronkowski is not alone in his investment in cannabis-based medicine for athletes. Joe Montana, Calvin Johnson, Ricky Williams, and Tiki Barber have all entered the cannabis space in ways, big and small. The NFL announced earlier this year it will study cannabis-based medicine as a pain management toll for athletes, and will consider changing its polices based on the research’s results.

Gronk’s announcement also highlights a growing trend of athletes retiring before their playing days ended from a physical perspective. Indianapolis Colts quarterback Andrew Luck stunned the sports world earlier this week, when he announced he was prematurely retiring from the NFL. Gronk explained why he was not returning to the NFL during his press conference.

“I want to be clear to my fans. I needed to recover. I was not in a good place. Football was bringing me down, and I didn’t like it. I was losing that joy in life,” he said.

Taste test: Should your guests taste that you’re cooking with cannabis?

Looking to add that special green ingredient to a home-cooked meal for friends? Perhaps your buddies are comfortable bud consumers, so no issues there. But what do you need to know about cooking with cannabis and what that means for taste?

The GrowthOp asked two Ontario chefs with a passion for cannabis cuisine for their best tips to make your next dinner party a smash: Jeff Kaminskas, a Toronto chef who has cooked with cannabis for decades and recently transitioned from food to craft vodka at Viritus Organics, and Reena Rampersad, a Hamilton, Ont.-based chef and owner of High Society Supper Club, a catering company that helps host upscale dinners and events for foodies who fancy a dash (or more) of cannabis in their cuisine.

Kaminskas and Rampersad wholeheartedly agree on a couple of critical points: There are multiple ways to work with cannabis flavours, and which ones yield the most delicious result is mostly up to the chef.

How does cannabis taste?

“It’s incredibly distinct,” says Kaminskas. “I’d say it’s got a nice sort of a spice, or provides a bittersweet additive, to whatever you want to cook with. It’s very much its own flavour,” he says.

“If you have your eyes closed, I’m sure that you could guess that it was likely a leafy vegetable, because I think you can taste a little bit of the chlorophyll. It’s a denser taste.” iStock / Getty Images Plus

“Cannabis is actually a very complex taste,” Rampersad suggests. “Once upon a time, people used to have single adjectives to describe it—but I guess, with us experiencing and exploring and discovering new strains—we’re finding that the taste is actually very full-bodied. I’d like to say that would be herb-y or dense,” she offers, but adds that “some strains taste very fruity, some taste very citrusy, some taste very piney.”

Both chefs agree the flavour is green. “You definitely know that you’re ingesting a plant, that’s for sure,” says Rampersad. “If you have your eyes closed, I’m sure that you could guess that it was likely a leafy vegetable, because I think you can taste a little bit of the chlorophyll. It’s a denser taste.”

Should the cannabis flavour be embraced or concealed?

Whether the flavour of cannabis is best as the star or relegated to a supporting role is a matter of personal taste. If cooking for guests who aren’t regular cannabis consumers, Kaminskas says the dish might go over better if the taste of cannabis doesn’t take centre stage. “A lot of the time, it’s better to try and cover it up because it is such a specific flavour,” he explains. If so, “you want to find other flavours that will contrast with or conceal it.” His recommendation? Playing with flavours such as chocolate, rosemary, garlic, or basil.

“You want to find other flavours that will contrast with or conceal it.” His recommendation? Playing with flavours such as chocolate, rosemary, garlic, or basil. iStock / Getty Images Plus

Kaminskas says experimentation is the best way to find a good culinary balance between the plant and the dish. “I really recommend trying different flavours that contrast or camouflage the taste.”

Rampersad offers a different approach, preferring to incorporate the flavour of the terpenes in the cultivar that she is working into her recipes. “If the terpene is humulene, for example, so it’s a little bit more woodsy, little bit more spicy. It resembles a nutmeg, cinnamon, spicy kind of thing all put together,” she says.

“Those [humulene-heavy cultivars] I find tend to go really nice with baked goods—if it’s a cookie or an earthier, flavoured type of batter, pancakes and things like that,” Rampersad says. There are also the piney and the fruity profiles, so “you also don’t want to hide the flavour.”

Are there natural food pairings?

For traditional pairings, such as fish, certain meats or even certain vegetable dishes “where you want a citrus punch, certainly that does apply as well,” says Rampersad.

But don’t just dump any cannabis in any recipe and expect it not to affect the dish’s taste; Rampersad recommends a bit of forethought and a bit of care to achieve a flavourful and complementary result.

“I find that when I do use a strain that has a lot of citrus tones, I will be able to detect that a bit in comparison to, say, a fish or any type of meat that gives a good contrast,” says Rampersad. However, if used in a dressing for a salad that has berries and peaches, those flavours might prevent the diner from picking out “the tones in that salad coming out of that strain.”

When making multiple infused courses or dishes, Rampersad likes to choose a flavour “theme” and stick with it to provide a coherent tasting experience. “I try not to put the same flavour profiles in the same meals with each other,” she says, adding she wouldn’t make a gingerbread cookie, which already has lots of ginger and spices in it, paired with a strain that has a lot of humulene. Or if the dish “had some floral tones in it, I might not use a strain that had linalool in it.”

Does it matter if you cook with cannabis oil, extract or flower?

The form of cannabis one cooks with is up to the chef, but Kaminskas advises against just throwing some dried flower into the recipe and calling it a day. Instead, he recommends trying infused oil or making canna-butter.

These butters “really go well into milk and fats,” says Kaminskas. “So, you could use that and, basically, combine the herb, if you will, into your fats.” The idea is not to dump “the actual flower itself directly into the dish. You just want all of the goodness contained therein.”

Kaminskas says that while infused oils may have a bit less of a taste, butters often put the cannabis flavour up front. “Once you actually combine the cannabis with the butter and you pressure cook that for hours and strain it out, by the end, you really get a lot of the actual flavour of the strain—so it’s really strain-dependent.”

And the more flavourful the cultivar, he says, the more it will affect the resulting butter. “When I cook, I like to use butter because they have so many different flavours across the spectrum. You could choose a really good strain that actually accents whatever else you’re cooking.”

A note on dosing: Optimal dosing of cannabis depends on both specific strains and the individual consuming them; questions should be directed to a healthcare professional. Any infused product should be handled with care, stored away from children and pets and clearly marked.

Smoking a bowl of high-THC Flower might be best for combatting pain

The average cannabis user living in states where marijuana is legal has the luxury of stepping inside his or her friendly neighborhood dispensary for access to a variety of pot products, like edible candies, pills, topicals, concentrates and even beverages. These processed variations of the cannabis plant are designed for those consumers who don’t necessarily want to smoke to achieve the desired effect. But when it comes to which method of consumption is best for patients suffering from chronic pain, a new study suggests that loading a bowl full of flower is still the most effective path to getting back to good.

Researchers at the University of New Mexico determined that people trying to manage pain through the use of cannabis are simply better off smoking bud than relying on other forms of the herb. The findings, which were published in the journal Complementary Therapies in Medicine, indicate that “whole cannabis flower was associated with greater pain relief than were other types of products.” The researchers go on to say that “higher tetrahydrocannabinol (THC) levels were the strongest predictors of analgesia and side effects prevalence across the five pain categories.”

These results are especially interesting considering that cannabidiol (CBD), the non-intoxicating compound of the cannabis plant, is now being praised as a rockstar at taming pain. Even the folks pushing the hemp-derived version of this medicine, which is much weaker than the oils made from marijuana, swear that this sometimes truck stop novelty is the key to living pain-free. However, researchers beg to differ. They have concluded that the presence of THC, which produces the stoned effects we all know and love, is also essential if the user expects any discernible pain-relief results.

“Cannabis flower with moderate to high levels of (THC) is an effective mid-level analgesic,” the study reads.

But it just isn’t the existence of THC that makes smoking marijuana the best approach to pain management.

We have swelled into a society convinced that dissecting cannabis and separating its components into good and evil is the right approach to the plant. This is perhaps the reason that CBD has risen to such stardom in the past five years. The problem with this attitude is that it completely disregards the 100 or so other cannabinoids that the cannabis plant has to offer. It also discounts essential terpenes and flavonoids and thereby eliminates any possibility that the patient will benefit from the plant’s synergistic properties. Science established long ago that the entourage effect associated with whole-plant cannabis is what truly provides the therapeutic effects. So, all of you military service members prohibited from using CBD products, don’t worry, you’re definitely not missing much.

But what about kids suffering from epilepsy? Dr. Sanjay Gupta told us years ago that they needed the CBD compound to stop seizures. Sure, while some sick children might have had some luck controlling this affliction through the use of CBD alone, a study published around this time last year found the compound was more effective at helping them stay seizure-free if it was complemented with just a hint of THC. Researchers found that the closer they got to allowing the two cannabinoids to work together, the better the results. “We saw a statistically significant reduction in motor seizures, and an increase in seizure-free days,” the study authors said.

Although the U.S. Food and Drug Administration (FDA) approved a CBD-based drug last year called Epidiolex to be prescribed to young patients suffering from two rare forms of epilepsy, not even it is expected to be a miracle cure. The drug, which contains absolutely no THC, is only effective in around 32% of patients, according to the FDA. Parents with epileptic kids have long complained that CBD alone just doesn’t do the trick and that the efficacy of this compound has been hyped beyond belief.

The latest study out of New Mexico, however, provides some guidance for an America looking for answers as to whether marijuana can relieve pain or not.

A separate study published earlier this week from the American Society of Anesthesiologists (ASA) shows that 75% of the U.S. population, most of them millennials, has a genuine interest in learning more about how pot can combat pain conditions. These folks, presumably those fed up with all of the anecdotal reports and the conflicting studies that emerge every other week, want to see the federal government finally roll up their sleeves on the cannabis issue and deliver real results.

Unfortunately, it seems that medical marijuana users are going to have to get high before they experience any noticeable pain relief. And that complicates things for a vast majority of the U.S. population — especially those in the workforce. Unlike over-the-counter pain remedies like acetaminophen and ibuprofen, which eliminate some of the hurt without a buzz, smoking marijuana to combat minor aches could lead to impairment issues on the job. Just like most companies don’t allow workers to drink booze on the clock, medical marijuana is not likely to be any different, even after federal legalization finally takes hold in the new few years. So, don’t sell your stock in Tylenol just yet.

Canadian Marijuana Sales Hit a New High in June, but This Doesn't Tell the Full Story

Chances are high -- pardon the pun -- that marijuana will be one of the greatest growth stories of our generation. With worldwide legal weed sales more than tripling between 2014 and 2018 to $10.9 billion, the research team of Arcview Market Research and BDS Analytics foresees sales climbing to more than $40 billion by 2024. Looking out even further, some of the most aggressive Wall Street estimates portend that global sales could hit $200 billion annually in about a decade's time.

While the United States should be the top-selling marijuana market in the world, it's Canada that tends to garner a lot of attention from investors. That's because last year Canada became the first industrialized country in the world -- and only the second overall behind Uruguay -- to legalize recreational cannabis. Canada is, therefore, something of a legalization guinea pig for the rest of the industrialized world to watch and potentially follow.

Chief among the statistics that investors watch closest are Canada's monthly cannabis sales. 

Canada's marijuana sales in June hit a record high

Last week, Statistics Canada released its monthly data on retail sales for June, with the country logging its highest marijuana sales figures to date. Below you'll find the progression of cannabis store sales since October 2018, as announced by Statistics Canada (all data is reported in Canadian dollars, with U.S. dollar equivalency in parenthesis):

  • October 2018: CA$53.68 million ($40.26 million)
  • November 2018: CA$53.73 million ($40.3 million)
  • December 2018: CA$57.34 million ($43.01 million)
  • January 2019: CA$54.88 million ($41.16 million)
  • February 2019: CA$51.66 million ($38.75 million)
  • March 2019: CA$60.94 million ($45.71 million)
  • April 2019: CA$74.58 million ($55.94 million)
  • May 2019: CA$85.81 million ($64.36 million)
  • June 2019: CA$91.13 million ($68.35 million)

Added up, licensed cannabis store revenue has tallied CA$583.75 million ($437.84 million) in the 8.5-month period since adult-use sales began in our neighbor to the north on Oct. 17. This should put Canada on track for perhaps CA$900 million (about $675 million) -- if not a tad bit higher -- in sales for its first full year.

A Canadian flag with a cannabis flag instead of a maple leaf and the words, Sold Out, stamped across the flag.

View photos

Supply issues are going to take a while to sort out

However, the roughly 6% sequential monthly sales growth in cannabis store sales in June doesn't tell the full story of the supply challenges Canada is currently contending with.

To begin with, Health Canada began the year with a monstrous backlog of cultivation, processing, and sales license applications for review. It often takes the regulatory agency many months, if not more than a year, to give the green light to a cultivation application, meaning it can take well over a year for a grow farm to become licensed to grow and sell cannabis. Some of the biggest growers in the world have been stymied by this licensing process, including Aphria (NYSE: APHA), which has been waiting for cultivation license approval for its Aphria Diamond facility for more than a year. Aphria Diamond will comprise 140,000 kilos of the company's 255,000 kilos of peak annual production.

If there is good news, it's that Health Canada has made changes to the application process to whittle away at its backlog. Growers now need to have their grow farms constructed and ready for inspection prior to submitting their cultivation license application. This should help remove underfunded growers from the equation and expedite the review process, but it's going to take Health Canada many quarters to work through its backlog.

In addition to supply issues created by licensing backlogs, Canada has been dealing with compliant packaging shortages. Health Canada laid out a laundry list of requirements that compliant packaging would need to follow in order to make it into licensed cannabis stores, and there simply hasn't been enough in the early going.

Making matters worse, despite some cannabis stocks having a substantive international presence, overseas sales have been virtually nonexistent because of these early stage supply and packaging issues. International sales are unlikely to pick up until demand in the Canadian market is being met, and that's probably not going to happen for many more quarters.

A hand reaching for a neat stack of hundred dollar bills in a mouse trap.

View photos

Investor expectations for pot stocks were always too high

All of these early stage problems for the Canadian cannabis market circle back to the reality that next-big-thing investments need time to mature.

Over the past quarter of a century, we've seen incredible rallies regarding blockchain, 3D printing, genomics, and business-to-business e-commerce, to name a few hot trends. However, each and every one of these rallies eventually came to a crashing halt. This isn't to say that companies within these industries weren't eventually fantastic long-term buys. But it does demonstrate that investors have a history of unrealistic expectations when it comes to next-big-thing industries -- and cannabis is no different. I don't doubt that cannabis sales can ramp up substantially over the long run, but with no precedence to a legal industrialized country, there will be bumps in the road.

Because of their premiums, the most popular pot stocks are likely to be the most exposed to wild swings lower in valuation. That means shareholders of Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), and Cronos Group (NASDAQ: CRON), which are three of the 11 most-held stocks on online investing app Robinhood, should be taming their near-term expectations.

In recent months, profit projections for all three companies have plunged. Aurora Cannabis, once expected to generate a modest profit of CA$0.10 per share (that's 10 Canadian cents) in fiscal 2020, is now forecast for a loss of CA$0.08 per share. Three months ago, Canopy Growth was forecast for CA$0.38 in full-year profit for fiscal 2021. Now Wall Street projects a loss of CA$0.73 per share. As for Cronos Group, its consensus estimate for 2020 has shrunk to a CA$0.01-per-share loss.

Even though Aurora Cannabis, Canopy Growth, and Cronos Group have all made intriguing acquisitions, pushed into foreign markets, and look to have the tools to succeed over the long run, supply and packaging issues have impacted all three pretty noticeably in the near term, and these headwinds aren't going to disappear overnight. Temper your expectations with cannabis stocks, and you won't be disappointed.